Associated Papers
Deep whole genome sequencing identifies recurrent genomic alterations in commonly used breast cancer cell lines and patient-derived xenograft models.
Deng N et al.
Breast Cancer Research : Bcr, 2022
36153537 (PubMed )
Supplement: 13058_2022_1540_MOESM2_ESM.xlsx › SuppTableS2
Establishment and Characterization of a Novel Human Ocular Adnexal Sebaceous Carcinoma Cell Line.
Rong AJ et al.
Translational Vision Science & Technology, 2021
34043754 (PubMed )
Supplement: tvst-10-6-34_s001.xlsx › 50_tum_norm_mutect.vcf.anno.hg3
Proteogenomics Reveals Perturbed Signaling Networks in Malignant Melanoma Cells Resistant to BRAF Inhibition.
Schmitt M et al.
Molecular & Cellular Proteomics : Mcp, 2021
34673281 (PubMed )
Supplement: mmc3.xlsx › S1
Somatic Mutation Profiles Revealed by Next Generation Sequencing (NGS) in 39 Chinese Hepatocellular Carcinoma Patients.
Ke L et al.
Frontiers in Molecular Biosciences, 2021
35118119 (PubMed )
Supplement: Table3.xlsx › sheet_1
A glioneuronal tumor with CLIP2-MET fusion.
Chowdhury T et al.
Npj Genomic Medicine, 2020
32550005 (PubMed )
Supplement: 41525_2020_131_MOESM2_ESM.xlsx › Mutation__exonic_splicing_
Mutational heterogeneity in non-serous ovarian cancers.
Teer JK et al.
Scientific Reports, 2017
28852190 (PubMed )
Supplement: 41598_2017_10432_MOESM2_ESM.xlsx › Supp_Table_11
Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.
Raaijmakers MI et al.
Oncotarget, 2016
27791198 (PubMed )
Supplement: oncotarget-07-77163-s002.xlsx › Patient_1_late_met_4
Select a paper to view details